Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

Part of paid clinical trials in Duarte, California.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT03667820
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Osimertinib — DRUG
    Osimertinib 80mg tablet to be taken once daily.
  • SABR — RADIATION
    Stereotactic Ablative Radiation (SABR)

Study Details

This study evaluates the combination of two well-tolerated therapies, osimertinib and Stereotactic Ablative Radiation (SABR).

Key Dates

Start date
Sep 26, 2018
Status verified
Oct 2025
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
41 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Osimertinib
    Osimertinib in combination with Stereotactic Ablative Radiation (SABR)

Primary Outcome Measure

Determine efficacy of Osimertinib plus SABR in patients with EGFR mutant lung cancer measured by Progression-Free Survival (PFS) [ Time Frame: Every 8 weeks from the time of first dose of study medication until subject death from any cause, assessed up to 300 weeks. ]

Locations (2)

FacilityCityStateZIPSite coordinators
City of Hope Medical CenterDuarteCalifornia91010-
University of Texas Southwestern Medical CenterDallasTexas75390-

Find similar trials in Duarte, CA

By research site
City of Hope Medical Center· Duarte, CAUniversity of Texas Southwestern Medical Center· Dallas, TX

Related Studies